Acaluxen (Acalabrutinib) 100 mg Capsules
29461₴
33858₴
-13%
Acaluxen 100 mg (Acalabrutinib) is a highly selective, second-generation Bruton's tyrosine kinase (BTK) inhibitor.
Manufacturer: Everest Pharmaceuticals. Each pack contains 60 capsules. By binding to the BTK enzyme, it inhibits the proliferation and survival of malignant B-cells. It is designed to be more targeted than first-generation inhibitors, potentially reducing off-target toxicities.
Key Feature:
Effective management of CLL and MCL with a generally favorable safety profile, particularly regarding cardiovascular risks compared to Ibrutinib.
Indicated for the treatment of adult patients with:
- 🔹 Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Both treatment-naive and relapsed/refractory patients.
- 🔹 Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy.
Packaging: 100 mg capsules.
⚠️ ADMINISTRATION PROTOCOL:
- Recommended Dose: 100 mg orally twice daily (approximately every 12 hours).
- Food Intake: Can be taken with or without food.
- Important Warning: ⛔ Avoid taking with proton pump inhibitors (PPIs) like omeprazole, as gastric acid is needed for absorption.
- Administration: Swallow whole with water. Do not chew, crush, or open capsules.
- Supply: One pack (60 caps) provides a full 30-day supply.
- Hypersensitivity to Acalabrutinib.
- Pregnancy and breastfeeding (risk of fetal harm).
- Severe bleeding disorders.
- Active severe infections.
Common adverse reactions include:
- 🤯 Headache: Very common (often manageable and diminishes over time).
- 🩸 Hematologic: Bruising, increased risk of bleeding/hemorrhage, neutropenia.
- 📉 Gastrointestinal: Diarrhea, nausea.
- 🦠 Infections: Upper respiratory tract infections.
100% original product
Delivery across Ukraine
Alternatives
View all in category
Similar products
Customer reviews
What Customers Say
No reviews yet
Your review can be the first!